Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Regnum Corp.
No Price
Closing Price OTC 30.04.2026:
0,0001 USD
30.04.2026 20:00
Current Prices from Regnum Corp.
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
UTC
RGMP
USD
30.04.2026 20:00
0,0001 USD
0,00 USD
Company Profile for Regnum Corp. Share
Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody C—C chemokine receptor type 5 antagonist, that is designed to prevent human immunodeficiency virus from entering human cells. The company is based in New York, New York. Regnum Corp. is a subsidiary of Phoenixus AG.
